This provides Pharmaceutical compositions comprising an activated form of enhanced human cannabinoid Receptor Antibody and its use in the treatment of Obesity and Related Metabolic Disorders.This also provides Pharmaceutical compositions comprising an activated form of enhanced human cannabinoid Receptor Antibody and enhanced an activated form of an Antibody to s-100 Protein for use in the treatment of Addiction to psychoactive substances.Claim 5: pharmaceutical Composition of claim 2, wherein the activated form of an Antibody is enhanced to a fraction of a polypeptide Human cannabinoid receptor 1.Claim 6: the pharmaceutical Composition of Claim 5, wherein the polypeptide fraction of Human cannabinoid receptor 1 is selected from the group consisting of sequences provided in SEQ ID no. 2 - 15.Claim 7: the pharmaceutical Composition of claim 1, wherein the activated form of an Antibody is enhanced in a mixture of Homeopathic dilutions C12, C30, and C200. Claim 12: the pharmaceutical Composition of claims 1 or 2, characterized by an enhanced Understanding additionally activated form of an Antibody to s-100 Protein.13: the pharmaceutical Composition of claim claim 12, wherein the Antibody to s-100 Protein is an Antibody to s-100 Protein. 14: the pharmaceutical Composition of claim claim 13, wherein the s-100 Protein is the sequence with SEQ ID no. 16.15: the pharmaceutical Composition of claim claim 12, wherein the Antibody to s-100 Protein is in the form of a mixture of Homeopathic dilutions C12, C30, and C200 impregnated in the solid Carrier.La presente provee composiciones farmacéuticas que comprenden una forma activada potenciada de un anticuerpo a receptor cannabinoide humano y al uso en el tratamiento de la obesidad y desórdenes metabólicos relacionados. La presente adicionalmente provee composiciones farmacéuticas que comprenden una forma activada potenciada de un anticuerpo a receptor cannabinoide humano y una forma activada potenciada de un anticuerpo a proteín
